pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-125b-2 |
Genomic Coordinates | chr21: 16590237 - 16590325 |
Synonyms | MIRN125B2, MIR125B2 |
Description | Homo sapiens miR-125b-2 stem-loop |
Comment | This miRNA sequence is predicted based on homology to a verified miRNA from mouse . |
RNA Secondary Structure | |
Associated Diseases |
Mature miRNA Information | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-125b-2-3p | ||||||||||||||
Sequence | 54| UCACAAGUCAGGCUCUUGGGAC |75 | ||||||||||||||
Evidence | Experimental | ||||||||||||||
Experiments | Cloned | ||||||||||||||
Editing Events in miRNAs |
|
||||||||||||||
SNPs in miRNA |
|
||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
miRNAs in Extracellular Vesicles |
|
Circulating MicroRNA Expression Profiling |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | FAM84B | ||||||||||||||||||||
Synonyms | BCMP101, NSE2 | ||||||||||||||||||||
Description | family with sequence similarity 84 member B | ||||||||||||||||||||
Transcript | NM_174911 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on FAM84B | |||||||||||||||||||||
3'UTR of FAM84B (miRNA target sites are highlighted) |
>FAM84B|NM_174911|3'UTR 1 TGGGCGAGCTGAGCGCAGAGCTGCGAAGGGGAACTGTTTGCAGTAGCAGCCGCTGCTCCCTTTCTCCCTCTCTTCCTCCC 81 TCTTTTGCCACTGTCTGGGCCCCATCTGGGATTCCTGGGCCCTTTGGAAAAGAGTTGGTGAAATGCGCAGCCGGCTGTGG 161 ACGGGGGAGGAGGAAGGGGACAGAGGGAGCAGGTAGGAAACACTTTAGTTGGGGGTGGGGGGCGTCTCCCTCTGGCCCCC 241 TGTCTGTCTTCCTCTCCGCGGTGGAGCAAACTGTGGACTTGCCTGGCACTTAAACCTTGGTAGATCTGGGTTTATAATCG 321 GCCATTCTTAAGCACGTGGGGTTGGGGGAAAGTTCGGAGTACCCATTCCTGCCGTTGCTTCCTATCCTGGGCTTGGAAGA 401 ATCCTGGTAGAAAGGCCAGAGTGGGTTTGTGGAGTCGCCACTGCGGGACCAGCACGAAAGCTGCTTGTCTGCTTTGGCGG 481 AGCTGAGCTGTGTATGGGATCCAGGAGGCTGGGGTGATTTATTTTATGGGATTCCTGGAGCGCAGGGCTGGTGAATCCAT 561 GACAAGGTCCGGGAGCAGCAGACCAAAACCACAGCAGCCTCCTATTAAGTGTAACAAATAGTTAAGCAAACTCGGGCTAC 641 AAACAAAGACTTTGCTACCTCCCTCCTCCACAACCCCCAAGTAATTAGCCTTCTGGAGCTGGCTCTTAGCTGAGGCTCCT 721 GCTACCTCCTGCTCCACCCGCCCCTTCCTAGGTTACAAGTAAATCATTGTCAAGGGCCAGCCAGGGGAAGGTTTCAATTA 801 AGGTTCTGTTCTGCTGCCTTTGTTTCTCCCCTGCTGTTGTAGGCACTTACAGCTGCGTTGTTATGAAAGGAGGGAATAGC 881 CCTTTGTGTCTTTGATCTAATTAAACCTGCTTGGCTGTGTTTATCCGCAGGGCAGGTCACAGATAGGGTTGGCTGTGCCA 961 CTCCATAAAGTATCTATTGTGGAAGCAGCCAAAAAGGGCTGCTGTGGCAGGAATTGGTTAATTTCTCCTTCCACTTCCCT 1041 TCCTGAATAGTGAAGGGAGCCCTTTTAAAACAAGGCTTTGGTGGTAATCCTGTGATTTTTTTTTCTCCCCCATCCCCTCA 1121 CTGGCCCATCCCTCTCACCCTCACTTTTGTTCTGCTGGTGGGTAAAATCTTAGGCTGAACACATATTTCAATGGTAAGAT 1201 ACTTATTTTGCTATCCACACTTGATGCAATTGAATTCAAGGTGCAAAGTCTTGTACTGAAGCAGTCTCCTTGTTGCTTGG 1281 AGAACACCTCCTTCAGAGCCCTTTGTTAAATAAGAGGGGCGACGTTGATCATAGATGCCACCTGGTTAGCACCGAATCTG 1361 ACTTTGGTGACAGTCCTAAAGCACAGTTGGTGATTGTGAGATCTGTTAGCGGCAGGCTGAGCAGATACTACTTGGTTTTG 1441 CTTGGTATGAGATACTACTGTTTGCTTAGTATGAGATTTTTTCCAGCCTGTCTCTTAAACTCCTGTGACATCTTCAATGA 1521 TATGTGCCCTCAGTTGCAGCATAGCTTCTCTGCTGCCTATTGCCATTGCTGTCTCAAAAGTTGAGTGAATTTTGAGGCGT 1601 CTTTTTTTTTTTTTCCTCTCTTGGGAGTCGTTGTAAACTACTGTGTACAAGTCATTTTGTGATATGATTCTGAACAGTTG 1681 GAATAGAATCATAGTTAAGTGGTACAGCCATGGCTATCGTCAGGCCTGTTGCCTGGAGATCTCTAAGTTAAGGCAACAAG 1761 ACTTAAAGAATTTTCTAATACACTTGTTTCACACATGGACGTTGAGGCCATAGTCTTTAAAAGCTTGGACCTTTGTAGCA 1841 CCTCAACATGAAAGGGCATTAGCTATGTTTCCTGTTTTTACAGTGATCACCAAACAGATCTTGCCACTTTGATTGTTAAA 1921 AATGAACCACATTCTAGCCCTGGTCTGGGACTTTGGAGGGAGATGAATTTCTTGTTGGAAATGTAAATCTAGTGTCCATA 2001 TTTAATACTCTCACAGCTTTGTGTTTATTCTCTTTGCTCATGGAATAGCAGAACAAGATAAACATGGGTTAAGACATTTA 2081 GGAGAACCTGCTGTATCTAACCCAGTTGGATTTTCTTTCATGCTTAACACAGTAGTGAAAATAGAAGGTAGGCCGGGCAC 2161 AGTGGCTCATGCCTGTAATCCCAGCACTTTGGGAGGCTGAGGCAGGTAGATCACCTGAAGTTAGGAGTTCGAGACCAGCC 2241 TGGCCAACATGGCGAAACCCTGTCTCTACCACAAATACAGAAAATTAGCTGGGCGTGGTGGCAGGCGCCTGTAATGCCTG 2321 CTACTTGGGAGCCTGAGGCAGAAGAATTGCTTGAAGCTGGGAAGCAGAGGTTGCAGTGAGCCGAGATCGCACCACTGCAC 2401 TCCAGCCTGGGCAGCAGAGCAAGTAGTAATAACCACCGTGTAGACAAGTGGGAGGGAAGAATAGAATGGCACTGTCCAGC 2481 TCTGGGCTAGCCAGATCAACTCCCCCACCCGTCTTCTTCCTCTGTCCCAGAATGGAAAATGATGTATGGTCAGTCACGCT 2561 GAAGTATAGCAGCGACTGTGTTAAGAGAGAGCAGTGACTCTCTCTTCTAGAGAAGAGGTTTTCAATAACAGGGCTTGGAA 2641 ATGAACTAGAATAGGAAATAGATCTTTTCAGATGCTGCTTTCCCATGTAATACAAGCGTTTCTACAGGGTACCAGAGGTG 2721 TGAAATATGTGACACTTAAGAACAGTGATTTTTATTGGGAATTTTCTTAGGGTTATTACACTTAAAGCAACAACCAACTA 2801 GTAACAGCTCCAGGAAAGGGGAATGAATCAACTCTTGGTTCTTTCCTGAAGACGGCAGTGTTGTGGATAAGTGAGTTTTT 2881 AATGCCCTGGCAGTGGCTACATTTGACACTTTAGAAAAAATAAACATATTTAATAATTTTTGTTTCTCCTTAGGAATAAG 2961 ACTGTAGAACTGTTTTGTACTGTGAATTACGGATGCTCTTTGAAGGAAAGAAATATCGATTCTAATGTTCTTCAGAAGTT 3041 CTGGCAGGGATAAGCAGGACATCGACTGGAACGTATGCTAAATGAAAGCAGACAAATTTCTATTTTCTTACCTGAGCAAA 3121 TATTTTATTGAAACTGCTTATGTATGTCAAAGGAGCCCACAACTTCAGCTACACAACTTTTTGTATTGAAAGAACTCATA 3201 CTTTTTGTAGCTTTTATTTCACATTTAATTTAAAGTGACTTTTAGCACTAAAATGCCTAGAAGATTTTACTCCAGACCTA 3281 TAAGGAAATGTTTAGTTTTTATGAAAAATGACAAGTCGATGGTTAAACTTCTCATGTCTTTGGTGCTTTGGCCCTAATAG 3361 CACTGGACAACACCACGACCACATGGAAACATATTTTTGGAAGCAAAACTTTAATTTTATATAACGTATGCTATGGAGAG 3441 CTAAGACAATTTAAGGACTACTTGTTTTCTATTTTTTTTCTTAATAAAATGGAATCCACTGTGTTGAAGACTCTTGATAT 3521 CATGTGCTTGTCTAACCATTTTTTGTTTTATAAATTAGAATAAAATATAGTTGTGATAATGGTCATCGAATGGATTTGTT 3601 TGGAAAGCTACATCTTATTTGTGAAATGTTTTTTAAATCAGAGTAACTATCAACTGATTCAGCTTTTTGTTGTTTTGTTC 3681 TTGGCTATAATACTTGTGACTCATGAAGAATTATGTTGACAAACAGGATAAATTCCACATGCATTTTATTTCCCAGTGAG 3761 TTGTATAAACTTTATTTTTGTTGAAGGTTGTATGTTAAATCAATGTTACATTCTTATATCACTTCTTGAGAAGGAAGTTC 3841 CGATTTGAAATTGTATCATTTCCTTCAAAATGAAGGGCAGTGCTTAGTTAAATAAAAGATTGATGATATCTTTTAAGCCA 3921 TTTCCTCTTCACTATGTCTTATTAAAATAAAACCTGTCAAGTTCTTTTCAAAAGATGCTATGAGCGTTTCCAATAAACCA 4001 TCTATTAGAGTTCACTGGAAAAAAAAAAAAAAAAAAAAAAA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | BC-3 |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in GSM796039. RNA binding protein: AGO2. Condition:4-Thiouridine
... - Gottwein E; Corcoran DL; Mukherjee N; et al., 2011, Cell host & microbe. |
Article |
- Gottwein E; Corcoran DL; Mukherjee N; et al. - Cell host & microbe, 2011
Primary effusion lymphoma (PEL) is caused by Kaposi's sarcoma-associated herpesvirus (KSHV) and frequently also harbors Epstein-Barr virus (EBV). The expression of KSHV- and EBV-encoded microRNAs (miRNAs) in PELs suggests a role for these miRNAs in latency and lymphomagenesis. Using PAR-CLIP, a technology which allows the direct and transcriptome-wide identification of miRNA targets, we delineate the target sites for all viral and cellular miRNAs expressed in PEL cell lines. The resulting data set revealed that KSHV miRNAs directly target more than 2000 cellular mRNAs, including many involved in pathways relevant to KSHV pathogenesis. Moreover, 58% of these mRNAs are also targeted by EBV miRNAs, via distinct binding sites. In addition to a known viral analog of cellular miR-155, we show that KSHV encodes a viral miRNA that mimics cellular miR-142-3p function. In summary, this study identifies an extensive list of KSHV miRNA targets, which are likely to influence viral replication and pathogenesis.
LinkOut: [PMID: 22100165]
|
CLIP-seq Support 1 for dataset GSM796039 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | BC-3 / 4-Thiouridine |
Location of target site | ENST00000304916.3 | 3UTR | UUGGCUAUAAUACUUG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 22100165 / GSE32109 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
91 hsa-miR-125b-2-3p Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT038624 | HN1L | Jupiter microtubule associated homolog 2 | 1 | 1 | ||||||||
MIRT038625 | KDELC2 | KDEL motif containing 2 | 1 | 1 | ||||||||
MIRT038626 | ABHD15 | abhydrolase domain containing 15 | 1 | 1 | ||||||||
MIRT038627 | PPP1R12C | protein phosphatase 1 regulatory subunit 12C | 1 | 1 | ||||||||
MIRT038628 | MSANTD4 | Myb/SANT DNA binding domain containing 4 with coiled-coils | 1 | 1 | ||||||||
MIRT038629 | ASH2L | ASH2 like histone lysine methyltransferase complex subunit | 1 | 1 | ||||||||
MIRT038630 | USP22 | ubiquitin specific peptidase 22 | 1 | 1 | ||||||||
MIRT038631 | CSTB | cystatin B | 1 | 1 | ||||||||
MIRT038632 | SYT2 | synaptotagmin 2 | 1 | 1 | ||||||||
MIRT038633 | NDUFS7 | NADH:ubiquinone oxidoreductase core subunit S7 | 1 | 1 | ||||||||
MIRT038634 | MTA2 | metastasis associated 1 family member 2 | 1 | 1 | ||||||||
MIRT053086 | IGF1R | insulin like growth factor 1 receptor | 3 | 1 | ||||||||
MIRT055788 | PLEKHA1 | pleckstrin homology domain containing A1 | 2 | 12 | ||||||||
MIRT061248 | AMOTL1 | angiomotin like 1 | 2 | 10 | ||||||||
MIRT061649 | BTG2 | BTG anti-proliferation factor 2 | 2 | 6 | ||||||||
MIRT079046 | TNRC6C | trinucleotide repeat containing 6C | 2 | 4 | ||||||||
MIRT084583 | BCL2L11 | BCL2 like 11 | 2 | 8 | ||||||||
MIRT093523 | GALNT7 | polypeptide N-acetylgalactosaminyltransferase 7 | 2 | 2 | ||||||||
MIRT097383 | LHFPL2 | LHFPL tetraspan subfamily member 2 | 2 | 4 | ||||||||
MIRT098030 | SOBP | sine oculis binding protein homolog | 2 | 2 | ||||||||
MIRT186262 | TCEB3 | elongin A | 2 | 2 | ||||||||
MIRT187284 | DAZAP2 | DAZ associated protein 2 | 2 | 10 | ||||||||
MIRT361113 | LRRC1 | leucine rich repeat containing 1 | 2 | 2 | ||||||||
MIRT443585 | FAM84B | family with sequence similarity 84 member B | 2 | 2 | ||||||||
MIRT452249 | TRAM1 | translocation associated membrane protein 1 | 2 | 2 | ||||||||
MIRT476289 | GMFB | glia maturation factor beta | 2 | 8 | ||||||||
MIRT483871 | MRPL12 | mitochondrial ribosomal protein L12 | 2 | 2 | ||||||||
MIRT484250 | ANK1 | ankyrin 1 | 2 | 2 | ||||||||
MIRT499251 | VAV3 | vav guanine nucleotide exchange factor 3 | 2 | 4 | ||||||||
MIRT502270 | HNRNPA1 | heterogeneous nuclear ribonucleoprotein A1 | 2 | 4 | ||||||||
MIRT504652 | RPL9 | ribosomal protein L9 | 2 | 6 | ||||||||
MIRT505210 | UBN2 | ubinuclein 2 | 2 | 6 | ||||||||
MIRT512690 | POP1 | POP1 homolog, ribonuclease P/MRP subunit | 2 | 2 | ||||||||
MIRT517341 | ZNF529 | zinc finger protein 529 | 2 | 4 | ||||||||
MIRT518946 | LSG1 | large 60S subunit nuclear export GTPase 1 | 2 | 2 | ||||||||
MIRT520866 | SUGT1 | SGT1 homolog, MIS12 kinetochore complex assembly cochaperone | 2 | 2 | ||||||||
MIRT521236 | SAR1A | secretion associated Ras related GTPase 1A | 2 | 2 | ||||||||
MIRT528324 | GIGYF2 | GRB10 interacting GYF protein 2 | 2 | 2 | ||||||||
MIRT533297 | USP46 | ubiquitin specific peptidase 46 | 2 | 2 | ||||||||
MIRT541024 | WEE1 | WEE1 G2 checkpoint kinase | 2 | 4 | ||||||||
MIRT544034 | ERRFI1 | ERBB receptor feedback inhibitor 1 | 2 | 2 | ||||||||
MIRT547037 | POGZ | pogo transposable element derived with ZNF domain | 2 | 2 | ||||||||
MIRT556102 | MOAP1 | modulator of apoptosis 1 | 2 | 2 | ||||||||
MIRT558320 | DR1 | down-regulator of transcription 1 | 2 | 2 | ||||||||
MIRT558520 | CSRNP3 | cysteine and serine rich nuclear protein 3 | 2 | 2 | ||||||||
MIRT566230 | PTMA | prothymosin, alpha | 2 | 4 | ||||||||
MIRT568437 | ARPP19 | cAMP regulated phosphoprotein 19 | 2 | 2 | ||||||||
MIRT570584 | OTUD7B | OTU deubiquitinase 7B | 2 | 2 | ||||||||
MIRT571384 | JKAMP | JNK1/MAPK8-associated membrane protein | 2 | 2 | ||||||||
MIRT572798 | SIGLEC14 | sialic acid binding Ig like lectin 14 | 2 | 2 | ||||||||
MIRT573864 | C9orf78 | chromosome 9 open reading frame 78 | 2 | 2 | ||||||||
MIRT609930 | SLC38A1 | solute carrier family 38 member 1 | 2 | 4 | ||||||||
MIRT610437 | CSMD2 | CUB and Sushi multiple domains 2 | 2 | 2 | ||||||||
MIRT614407 | MURC | caveolae associated protein 4 | 2 | 2 | ||||||||
MIRT618625 | GREB1 | growth regulation by estrogen in breast cancer 1 | 2 | 2 | ||||||||
MIRT620605 | SAP30 | Sin3A associated protein 30 | 2 | 2 | ||||||||
MIRT635313 | FAM179A | TOG array regulator of axonemal microtubules 2 | 2 | 2 | ||||||||
MIRT635918 | GLTSCR2 | NOP53 ribosome biogenesis factor | 2 | 2 | ||||||||
MIRT638507 | MAP3K9 | mitogen-activated protein kinase kinase kinase 9 | 2 | 2 | ||||||||
MIRT640597 | TM9SF4 | transmembrane 9 superfamily member 4 | 2 | 2 | ||||||||
MIRT644066 | IQCE | IQ motif containing E | 2 | 2 | ||||||||
MIRT648287 | TRAPPC2L | trafficking protein particle complex 2 like | 2 | 2 | ||||||||
MIRT653089 | SSR3 | signal sequence receptor subunit 3 | 2 | 2 | ||||||||
MIRT654651 | PTAFR | platelet activating factor receptor | 2 | 2 | ||||||||
MIRT658084 | FOXR2 | forkhead box R2 | 2 | 2 | ||||||||
MIRT665306 | ZBTB37 | zinc finger and BTB domain containing 37 | 2 | 2 | ||||||||
MIRT665974 | SYTL4 | synaptotagmin like 4 | 2 | 2 | ||||||||
MIRT674905 | RASSF9 | Ras association domain family member 9 | 2 | 2 | ||||||||
MIRT680085 | THAP1 | THAP domain containing 1 | 2 | 2 | ||||||||
MIRT681487 | DIP2A | disco interacting protein 2 homolog A | 2 | 2 | ||||||||
MIRT691243 | DFNB59 | pejvakin | 2 | 2 | ||||||||
MIRT692361 | AGTRAP | angiotensin II receptor associated protein | 2 | 2 | ||||||||
MIRT693034 | MB21D1 | Mab-21 domain containing 1 | 2 | 2 | ||||||||
MIRT694478 | LRTOMT | leucine rich transmembrane and O-methyltransferase domain containing | 2 | 2 | ||||||||
MIRT696069 | ZNF264 | zinc finger protein 264 | 2 | 2 | ||||||||
MIRT696579 | TTC21B | tetratricopeptide repeat domain 21B | 2 | 2 | ||||||||
MIRT696759 | MTFMT | mitochondrial methionyl-tRNA formyltransferase | 2 | 2 | ||||||||
MIRT697306 | ZNF652 | zinc finger protein 652 | 2 | 2 | ||||||||
MIRT698736 | STX12 | syntaxin 12 | 2 | 2 | ||||||||
MIRT701055 | PARP2 | poly(ADP-ribose) polymerase 2 | 2 | 2 | ||||||||
MIRT701197 | OTUD3 | OTU deubiquitinase 3 | 2 | 2 | ||||||||
MIRT701334 | NSD1 | nuclear receptor binding SET domain protein 1 | 2 | 2 | ||||||||
MIRT703617 | FBXO45 | F-box protein 45 | 2 | 2 | ||||||||
MIRT708893 | ZNF780A | zinc finger protein 780A | 2 | 2 | ||||||||
MIRT711621 | DGKH | diacylglycerol kinase eta | 2 | 2 | ||||||||
MIRT713744 | TMEM81 | transmembrane protein 81 | 2 | 2 | ||||||||
MIRT715060 | TMTC1 | transmembrane and tetratricopeptide repeat containing 1 | 2 | 2 | ||||||||
MIRT719711 | CD101 | CD101 molecule | 2 | 2 | ||||||||
MIRT720293 | DLGAP3 | DLG associated protein 3 | 2 | 2 | ||||||||
MIRT722605 | CCDC152 | coiled-coil domain containing 152 | 2 | 2 | ||||||||
MIRT724565 | ACSBG1 | acyl-CoA synthetase bubblegum family member 1 | 2 | 2 |
miRNA-Drug Associations | ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|